Paul M. Harari, MD Print Friendly PageChair, Department of Human Oncology
Faculty, University of Wisconsin School of Medicine and Public Health
Dr. Harari’s medical interests include radiation oncology, head and neck oncology, and oncology training and education.
UW Health Clinics
UW School of Medicine and Public Health
|Department of Human Oncology|
Professional Certifications and Education
University of Arizona Medical Center
University of California-Davis Medical Center, Sacramento
University of Virginia School of Medicine, Charlottesville, VA, 1984
|Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.|
Our doctors provide a wide range of services. The following list represents some, but not all, of the procedures offered by this physician.
Dr. Harari's clinical and laboratory research focuses on treatment advances for head and neck cancer patients through precision radiation techniques and the use of molecular targeted growth inhibitors combined with radiation.
Morris ZS Saha S Magnuson WJ Morris BA Borkenhagen JF Ching A Hirose G McMurry V Francis DM Harari PM Chappell R Tsuji S Ritter MA .
Increased tumor response to neoadjuvant therapy among rectal cancer patients taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Cancer. 2016 May 20;
[PubMed ID: 27203227]
Barasch S Mohindra P Hennrick K Hartig GK Harari PM Yang DT .
Assessing p16 Status of Oropharyngeal Squamous Cell Carcinoma by Combined Assessment of the Number of Cells Stained and the Confluence of p16 Staining: A Validation by Clinical Outcomes. Am J Surg Pathol. 2016 May 16;
[PubMed ID: 27186851]
Rosenthal DI Harari PM Giralt J Bell D Raben D Liu J Schulten J Ang KK Bonner JA .
Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab. J Clin Oncol. 2016 Apr 20;34(12):1300-8
[PubMed ID: 26712222]
Mohindra P Urban E Pagan JD Geye HM Patel VB Bayliss RA Bender ET Harari PM .
Selective omission of level V nodal coverage for patients with oropharyngeal cancer: Clinical validation of intensity-modulated radiotherapy experience and dosimetric significance. Head Neck. 2016 Apr;38(4):499-505
[PubMed ID: 25445257]
Yan Y Yadav P Bassetti M Du K Saenz D Harari P Paliwal BR .
Dosimetric differences in flattened and flattening filter-free beam treatment plans. J Med Phys. 2016 Apr-Jun;41(2):92-9
[PubMed ID: 27217620]
Bar-Ad V Zhang QE Harari PM Axelrod R Rosenthal DI Trotti A Jones CU Garden AS Song G Foote RL Raben D Shenouda G Spencer SA Harris J Le QT .
Correlation Between the Severity of Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer Patients: The RTOG Experience. Int J Radiat Oncol Biol Phys. 2016 Mar 26;
[PubMed ID: 27212198]
Francis DM Huang S Armstrong EA Werner LR Hullett C Li C Morris ZS Swick AD Kragh M Lantto J Kimple RJ Harari PM .
Pan-HER Inhibitor Augments Radiation Response in Human Lung and Head and Neck Cancer Models. Clin Cancer Res. 2016 Feb 1;22(3):633-43
[PubMed ID: 26420857]
Wojcieszynski AP Rosenberg SA Brower JV Hullett CR Geurts MW Labby ZE Hill PM Bayliss RA Paliwal B Bayouth JE Harari PM Bassetti MF .
Gadoxetate for direct tumor therapy and tracking with real-time MRI-guided stereotactic body radiation therapy of the liver. Radiother Oncol. 2016 Feb;118(2):416-8
[PubMed ID: 26627702]
Hoffman MR McCulloch TM Mohindra P Das R Geurts M Harari PM .
Simulation study of high-dose-rate brachytherapy for early glottic cancer. Brachytherapy. 2016 Jan-Feb;15(1):94-101
[PubMed ID: 26614234]
Britt CJ Stein AP Patel PN Harari PM Hartig GK .
Incidental Parotid Neoplasms: Pathology and Prevalence. Otolaryngol Head Neck Surg. 2015 Oct;153(4):566-8
[PubMed ID: 26019135]
Werner LR Huang S Francis DM Armstrong EA Ma F Li C Iyer G Canon J Harari PM .
Small Molecule Inhibition of MDM2-p53 Interaction Augments Radiation Response in Human Tumors. Mol Cancer Ther. 2015 Sep;14(9):1994-2003
[PubMed ID: 26162687]
Li C Huang S Armstrong EA Francis DM Werner LR Sliwkowski MX van der Kogel A Harari PM .
Antitumor Effects of MEHD7945A, a Dual-Specific Antibody against EGFR and HER3, in Combination with Radiation in Lung and Head and Neck Cancers. Mol Cancer Ther. 2015 Sep;14(9):2049-59
[PubMed ID: 26141946]
Morris ZS Weichert JP Saker J Armstrong EA Besemer A Bednarz B Kimple RJ Harari PM .
Therapeutic combination of radiolabeled CLR1404 with external beam radiation in head and neck cancer model systems. Radiother Oncol. 2015 Sep;116(3):504-9
[PubMed ID: 26123834]
Kim H Monroe JI Lo S Yao M Harari PM Machtay M Sohn JW .
Quantitative evaluation of image segmentation incorporating medical consideration functions. Med Phys. 2015 Jun;42(6):3013-23
[PubMed ID: 26127054]
Magnuson WJ Urban E Bayliss RA Harari PM .
Impact of Node Negative Target Volume Delineation on Contralateral Parotid Gland Dose Sparing Using IMRT in Head and Neck Cancer. Technol Cancer Res Treat. 2015 Jun;14(3):315-9
[PubMed ID: 25782188]
Stein AP Britt CJ Saha S McCulloch TM Wieland AM Harari PM Hartig GK .
Patient and tumor characteristics predictive of primary parotid gland malignancy: A 20-year experience at the University of Wisconsin. Am J Otolaryngol. 2015 May-Jun;36(3):429-34
[PubMed ID: 25766621]
Kimple RJ Harari PM .
The prognostic value of HPV in head and neck cancer patients undergoing postoperative chemoradiotherapy. Ann Transl Med. 2015 May;3(Suppl 1):S14
[PubMed ID: 26046059]
Stein AP Swick AD Smith MA Blitzer GC Yang RZ Saha S Harari PM Lambert PF Liu CZ Kimple RJ .
Xenograft assessment of predictive biomarkers for standard head and neck cancer therapies. Cancer Med. 2015 May;4(5):699-712
[PubMed ID: 25619980]
Nyflot MJ Kruser TJ Traynor AM Khuntia D Yang DT Hartig GK McCulloch TM Wiederholt PA Gentry LR Hoang T Jeraj R Harari PM .
Phase 1 trial of bevacizumab with concurrent chemoradiation therapy for squamous cell carcinoma of the head and neck with exploratory functional imaging of tumor hypoxia, proliferation, and perfusion. Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):942-51
[PubMed ID: 25659884]
Schwartz DL Harris J Yao M Rosenthal DI Opanowski A Levering A Ang KK Trotti AM Garden AS Jones CU Harari P Foote R Holland J Zhang Q Le QT .
Metabolic tumor volume as a prognostic imaging-based biomarker for head-and-neck cancer: pilot results from Radiation Therapy Oncology Group protocol 0522. Int J Radiat Oncol Biol Phys. 2015 Mar 15;91(4):721-9
[PubMed ID: 25752384]